Vodobatinib clinical trials
Also written K0706.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses vodobatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- K0706
- 4
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses vodobatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML TherapiesTerminatedPhase 1/2Sun Pharma Advanced Research Company LimitedNCT02629692Written as Vodobatinib (K0706) capsulesHow we know
- PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706TerminatedPhase 2Sun Pharma Advanced Research Company LimitedNCT03655236Written as K0706How we know
- Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseCompletedPhase 1Sun Pharma Advanced Research Company LimitedNCT02970019Written as K0706How we know
- To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy VolunteersCompletedPhase 1Sun Pharma Advanced Research Company LimitedNCT03445338Written as K0706How we know
- Bioavailability Study of K0706 in Healthy SubjectsCompletedPhase 1Sun Pharma Advanced Research Company LimitedNCT03316820Written as K0706How we know
Codes
What other systems call vodobatinib · ClinicalTrials.gg INT017365
- UNII (FDA) N8Q12KU2SWVODOBATINIBOne source FDA
- NCI Thesaurus C174748VodobatinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N8Q12KU2SW | VODOBATINIB | One source FDA |
| NCI Thesaurus | C174748 | Vodobatinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.